novo nordisk glp-1 patent litigation The Heavy Price of Drugs – I-MAK Novo Nordisk drops lawsuit against

Description

doi: 10.1161/HYPERTENSIONAHA.109.130203 31 HermidaRCCrespoJJDominguez-SardinaMOteroAMoyaARiosMTet al

Once-weekly semaglutide as adjunct to automated insulin delivery in adults with type 1 diabetes: a randomised crossover trial

The most recent developments regarding therapies based on incretin hormones (glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP)) are likely to fundamentally change our therapy for type 2 diabetes mellitus (T2DM), obesity and conditions associated with diabetes and obesity, i

Factors such as the rising prevalence of type 2 diabetes, higher treatment demand, and increased prescriptions for GLP-1 receptor agonist medications are all contributing to the segment's expansion